New Mexico

GUIDE FOR COMMUNITY ADVOCATES ON THE OPIOID SETTLEMENT

Total Funds

$195 million\(^1\)

Allocation

55% to local governments and 45% to the state

Mechanism

Allocation agreement between the state and local governments (New Mexico Opioid Allocation Agreement), legislation (N.M. Stat. Ann. §§ 6-4-28 and 6-4-29)\(^2\)

Key Takeaways

Opioid Settlement Restricted Fund, Crisis Recovery Fund. State law creates the Opioid Settlement Restricted Fund to hold the state’s share of settlement monies, and the Opioid Crisis Recovery Fund which receives a defined distribution from the Restricted Fund each year for opioid remediation spending by the legislature.\(^3\)

Permitted uses. There are differences between how the Allocation Agreement defines eligible expenditures, which governs only the Distributor and Janssen settlements, relative to authorized opioid remediation uses in state law for the Opioid Crisis Recovery Fund.\(^4\)

Public reporting. New Mexico has made no explicit promises to publicly report opioid settlement expenditures.

Background

New Mexico state law establishes the Opioid Settlement Restricted Fund (Restricted Fund) and the Opioid Crisis Recovery Fund (Recovery Fund), and defines opioid remediation expenditures.\(^5\) The New Mexico Opioid Allocation Agreement (Agreement) directs 45% of funds to the state and 55% to local governments, but this specific allocation governs monies from the Distributor and Janssen settlements only.\(^6\) Both state law and the Agreement address permitted uses of funds’ with some contrasts.

Under the Agreement, which applies only to the Distributor and Janssen settlements, all funds regardless of their allocation must be utilized for Opioid Related Expenditures.\(^7\) Opioid Related Expenditures are defined as spending consistent with Exhibit E of the Distributor and Janssen settlements (included word for word in the Agreement as Exhibit B), which includes treatment, prevention, harm reduction, and recovery supports.\(^8\) Importantly, local governments may not use funds from their share for reimbursement of past expenses.\(^9\)

This resource is current as of 6/5/2023. For the most up-to-date information, please visit https://www.opioidsettlementtracker.com/settlementspending.
State law governs the use of monies from the Opioid Restricted and Recovery Funds, which do not include the 55% local government share of the Distributor and Janssen settlements. Spending via legislative appropriations from the Recovery Fund must be toward “opioid remediation expenditures,” defined as expenditures on care, treatment, and other programs consistent with the distributor settlement. This definition is not confined to forward-looking expenditures and state law also stipulates that the Recovery Fund is to be used for statewide and regional programs, with priority given to evidence-based strategies that address the needs of individuals impacted by the justice system, reduce “opioid-related harms,” and provide treatment and connections to care, amongst other goals. A portion of monies from the Recovery Fund may also be allocated toward research or evaluation efforts.

55% LOCAL GOVERNMENT SHARE
The Allocation Agreement (Agreement) directs 55% of funds to Local Governments. As described above, the allocation shares from the Agreement apply only to the Distributor and Janssen settlements. The 55% share of funds going to local governments is divided across Regions—a Region can take different forms, such as a single city (e.g., Albuquerque City) or a county and all of its participating cities (e.g., Eddy County alongside Artesia City and Carlsbad City). The share of funds going to each Region can be found in Exhibit C of the Agreement. When a Region has more than one member, the members can collectively agree to have the funds shared amongst themselves in any manner they choose but absent a specific agreement, the default allocation from Exhibit G of the national settlements applies. Local governments are free to pool their portions of the Local Government Share (LG Share) with one another or with the state. The Agreement also provides for 15% of the LG Share to be deposited into the New Mexico Backstop Fund for the compensation as needed of attorneys for litigating local
Decision-Making Process (Continued)

LOCAL SPENDING EXAMPLE
In January 2023, the Bernalillo County Commission approved the use of $975,000 in settlement funds to support an 11-month marketing campaign, community awareness training and presentation, and improvements to the website keepNMalive.com to be a more comprehensive resource.23

governments who did not recover an amount equal to a 15% contingency fee via the National Attorney Fee Fund.19 The cost of a settlement administrator is divided evenly between the state’s share and localities’ share.20

Counties and cities receiving funds from the LG Share must designate a separate LG Abatement Fund for receiving and expending their funds and this may not be commingled with other monies.21 Funds in an LG Abatement Fund may only be used toward Opioid Related Expenditures, i.e., forward-looking spending consistent with Exhibit E of the national settlements.22 Outside of these requirements, funds from the LG Share will likely be expended according to normal budget processes.

45% STATE SHARE
Forty-five percent (45%) of New Mexico’s opioid settlement monies from the Distributor and Janssen settlements are allocated to the state.24 Aside from the state’s contribution toward half of the cost for a settlement administrator under the Agreement, these funds must be utilized only for Opioid Related Expenditures.25

The state’s 45% share is ostensibly placed in the Opioid Settlement Restricted Fund (Restricted Fund).26 Created by state law, this is a non-reverting fund in the state treasury that is separate from the general fund.27 The Restricted Fund includes monies from the Distributor and Janssen settlements and “opioid settlements” broadly speaking,28 but expressly excludes the Local Government Share from the Agreement.29 Money from the Restricted Fund may only be appropriated to the Opioid Crisis Recovery Fund (Recovery Fund) and for no other purpose.30 State law establishes 5% distributions from the Restricted Fund to the Recovery Fund starting in July 2024 and ongoing.31 Once monies are placed in the non-reverting Recovery Fund, they are expended through legislative appropriation and may only go toward opioid remediation expenditures.32

OPIOID REMEDIATION EXPENDITURES FROM THE OPIOID CRISIS RECOVERY FUND
• Legislative appropriation needed to spend from the Recovery Fund.
• Statewide and regional programs.
• Priority to evidence-based strategies33 that address goals listed in state law34 and portion of funds authorized for research or evaluation on outcomes from disbursement of Recovery Fund monies.35
• Spending is consistent with the distributor settlement agreement.36
Tracking Funds and Accountability

- There is no requirement in New Mexico’s Allocation Agreement or in state law for public reporting on opioid settlement expenditures at the state or local levels.\(^{37}\)
- New Mexico law provides for an annual audit, which will include a review of the state’s share of settlement funds and each LG Abatement Fund.\(^{38}\) Where misspending is identified, the state or local government must redirect funds from another source to an Opioid Related Expenditure to be eligible for further settlement distributions.\(^{39}\) There are not enforcement provisions in the Agreement or in state law outside of this audit process.

Engaging in the Process

- New Mexico has fewer obvious channels to engage on settlement spending than many states. Push for that to change! Reach out to the state and your local government for more information on how settlement funds will be spent in your community.
- Encourage opportunities for community input on the use of funds at the state and local levels. For example, the state and/or its localities could create advisory bodies that include directly impacted people or hold townhalls to receive public feedback.
- Monitor legislative appropriations, which is how monies from the Recovery Fund will be spent.
- Learn more about the Overdose Prevention and Pain Management Advisory Council (Council). The Council does not have a stated role on opioid settlement spending in any of New Mexico’s mechanisms, but it is charged with “reviewing the status of overdose prevention and pain management standards and education efforts.”\(^{40}\) You can subscribe to updates, view minutes and information about future meetings, or even submit an application to participate here. For questions, contact Paul Maldonado (paul.maldonado@state.nm.us).
Additional Resources

NEW MEXICO DEPARTMENT OF HEALTH
Opioid Safety & Overdose Prevention

Harm Reduction Program

Resources

OPIOID PREVENTION AND PAIN MANAGEMENT ADVISORY COUNCIL
2020 Advisory Council Recommendations

Current Members List

A Dose of Reality, including a treatment locator and information on where to obtain naloxone

ASTHO BRIEF
The Role of Syringe Services Programs in New Mexico’s Opioid Crisis Response (2021)
1. From settlements with distributors McKesson, AmerisourceBergen, Cardinal Health and manufacturer Johnson & Johnson only. New Mexico has also individually resolved other litigation against, e.g., retail pharmacy chain operators Walmart, CVS, Albertsons, and Kroger Co. See “Attorney General Balderas Announced $132 Million in Opioid Settlements with Walmart, CVS, and Albertsons” and “Attorney General Balderas Announces $58.5 Million Opioid Settlement with Smith’s Food & Drug Parent, the Kroger Co.” See KHN’s “The Right to Know: Where Does Your State Stand on Public Reporting of Opioid Settlement Cash?” interactive transparency map (located mid-article; click “New Mexico” for state-specific participation information) and OpioidSettlementTracker.com’s Global Settlement Tracker for more information.

2. New Mexico’s Allocation Agreement is limited by its definitions to the Distributor and Janssen settlement. See Agreement A.7. However, state law establishing the opioid settlement restricted fund and the opioid crisis recovery fund encompasses the Distributor and Janssen settlement as well as “opioid settlements,” which are defined as “judgments or settlements arising from the liability of distributors of opioids, manufacturers of opioids, pharmacies for the selling of opioids or the consultants, agents or associates of distributors, manufacturers, or pharmacies.” See N.M. Stat. Ann. § 6-4-28(A)(1)-(2) and (H)(5). Note that many states’ mechanisms for opioid settlement spending were designed to comply with the requirements of the Distributor and Janssen settlement agreements, which require (among other provisions) that a minimum of 85% of settlement funds be spent on opioid remediation expenditures. Section V.B.1. Subsequent settlements require varying thresholds of opioid remediation spend; the CVS and Walgreens agreements, for instance, require a minimum of 95.5% and 95% opioid remediation spending, respectively. Section V.B.1. Keep an eye out for the ways states will amend their spending mechanisms, if at all, to comply with subsequent settlement terms.

5. N.M. Stat. Ann. §§ 6-4-28, 6-4-29(D)(1)-(9) and (F)(3).
6. Agreement B.3, A.7 and A.8.
7. See N.M. Stat. Ann. § 6-4-29(D)(1)-(9) and Agreement B.6, A.3, Exhibit B.
8. Agreement B.6. Note that there are limited exceptions for funds directed toward the New Mexico Backstop Fund to cover local governments’ attorneys’ fees. Agreement B.3.
9. Agreement A.3, Exhibit B.
10. Agreement C.2.
12. N.M. Stat. Ann. § 6-4-29(F)(3); See Distributor settlement (Section I.SS) (“Opioid Remediation” means care, treatment, and other programs and expenditures (including reimbursement for past such programs or expenditures except where this Agreement restricts the use of funds solely to future Opioid Remediation) designed to (1) address the misuse and abuse of opioid products, (2) treat or mitigate opioid use or related disorders, or (3) mitigate other alleged effects of the opioid abuse crisis, including on those injured as a result of the opioid abuse crisis. Exhibit E provides a non-exhaustive list of expenditures that qualify as being paid for Opioid Remediation. Qualifying expenditures may include reasonable related administrative expenses.”)
13. An “evidence-based” activity, program, or strategy meets one or more of the following criteria: 1) systematic reviews or meta analyses have found it is effective; 2) evidence from a scientifically rigorous study demonstrates it is effective; 3) multiple observational studies from locations in the U.S. indicate it is effective See N.M. Stat. Ann. § 6-4-29(F)(2)(a)-(c).
14. N.M. Stat. Ann. § 6-4-29(B), (F)(1)-(9).
16. “Region” consists of either: (1) a single Participating County that does not have any Participating Cities, (2) a single Participating County and all of its Participating Cities or (3) a single Participating City. Two or more Regions may at their discretion form a group (“Multicounty Region”). Regions that do not choose to form a Multicounty Region will be their own Region.” Agreement B.4.
17. Agreement B.5.
19. Agreement D.3.
23. “County Commission Approved Opioid Settlement Funds for Fentanyl Prevention Education and Awareness Campaign.”
26. Note that legislation creating the Restricted Fund was signed by the governor only two days before legislative appropriations of approximately $21 million to six New Mexico agencies and the University of New Mexico, which may be expended through FY2024. The agencies are the Early Childhood Education and Care Department, Human Services Department, Department of Health, Children, Youth and Families Department, Corrections Department, and Public Education Department. See HB2, the General Appropriations Act of 2023, Section 11 (Additional Supplemental Health and Human Services Appropriations). See also “Drug Money: New Mexico to use $500M in settlement funds to aid in opioid recovery and prevention efforts.” It is unclear what proportion of this $21 million was derived from the state’s 45% share of the Distributor and Janssen settlements versus monies from settlements with other defendants. For example, in December 2022, state Attorney General Balderas announced the resolution of litigation against retail pharmacy chain operators Walmart, CVS, and Albertsons that resulted in over $132 million for New Mexico. See “Attorney General Balderas Announces $132 Million in Opioid Settlements with Walmart, CVS, and Albertsons”.
28. “Opioid settlements” is defined in state law as “judgments or settlements arising from the liability of distributors of opioids, manufacturers of opioids, pharmacies for the selling of opioids or the consultants, agents or associates of distributors, manufacturers or pharmacies.” N.M. Stat. Ann. § 6-4-28(H)(5).
31. The first of these distributions will occur on July 1, 2024 and will be equal to “five percent of the average year-end market value of the opioid settlement restricted fund for the immediately preceding fiscal year.” N.M. Stat. Ann. § 6-4-28(E). In July 2025, the distribution is calculated based on the preceding two calendar years. N.M. Stat. Ann. § 6-4-28(F). Beginning in July 2025 and thereafter, the distribution is equal to 5% of the average of the year-end market values of the Restricted Fund for preceding three calendar years. N.M. Stat. Ann. § 6-4-28(F).
32. N.M. Stat. Ann. § 6-4-29(B).
33. An “evidence-based” activity, program, or strategy meets one or more of the following criteria: 1) systematic reviews or meta analyses have found it is effective; 2) evidence from a scientifically rigorous study demonstrates it is effective; 3) multiple observational studies from locations in the U.S. indicate it is effective See N.M. Stat. Ann. § 6-4-29(F)(2)(a)-(c).
34. State law identifies nine different goals, such as providing treatment and connections to care, addressing the needs of pregnant or parenting women with OUD or people impacted by the justice system, prevention of opioid over-prescribing, and wellness and support services for first responders. N.M. Stat. Ann. § 6-4-29(D)(1)-(9).
35. N.M. Stat. Ann. § 6-4-29(E).
36. N.M. Stat. Ann. § 6-4-29(F)(3)(a)-(c); See Distributor settlement definition of “opioid remediation” (Section I.SS). (“Opioid Remediation” means care, treatment, and other programs and expenditures (including reimbursement for past such programs or expenditures except where this Agreement restricts the use of funds solely to future Opioid Remediation) designed to (1) address the misuse and abuse of opioid products, (2) treat or mitigate opioid use or related disorders, or (3) mitigate other alleged effects of the opioid abuse crisis, including on those injured as a result of the opioid abuse crisis. Exhibit E provides a non-exhaustive list of expenditures that qualify as being paid for Opioid Remediation. Qualifying expenditures may include reasonable related administrative expenses.”)
37. See OpioidSettlementTracker.com’s “States’ Initial Promises to Publicly Report their Opioid Settlement Expenditures”.
38. See Agreement C.3. N.M. Stat. Ann. §§ 12-6-1 – 12-6-15 (Audit Act); note that these provisions around annual audit for state and local agencies are not specific to opioid settlement funds or spending.
39. Agreement C.3. The State Auditor must confirm this “redirection” of funding has occurred.
40. Opioid Safety Provider Resources—About the Advisory Council.